12:34 AM EDT, 09/23/2026 (MT Newswires) -- Carvolix (CVX.PA) submitted a 510(k) application to the US Food and Drug Administration for the Tavipilot Robot, the robotic component of its platform for transcatheter aortic valve replacement procedures. The robot uses artificial intelligence-driven technology to provide catheter stability and millimetric precision control under the operator's supervision, the French medical technology company said in a Tuesday release. The US FDA clearance is a condition for the company to draw the second 10 million-euro tranche under a 30 million-euro structured debt facility secured with Claret Capital. If approved, Carvolix plans to commercially launch the platform in the US by early 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.